International Alliance for Personalised Medicine shared on LinkedIn:
“Behind Every 300 Patients Is One Patient.
Imagine a clinical trial of 300 patients.
For the health system, it is a dataset. For the regulator, it is evidence. For the researcher, it may answer an important scientific question.
But for the individual patient, there is only one question: what does this mean for me?
If you happen to be on the wrong side of an average, a biomarker threshold or a waiting list, the statistical logic of 300 patients suddenly becomes intensely personal.
That is the starting point for the International Alliance for Personalised Medicine’s conference in Dublin on 2 October: “Innovation and Securing Patient Access to Personalised Medicine.
The discussion begins not with technology, but with one patient. A patient develops symptoms. What happens next?
Can disease be detected early enough? Is the right diagnostic test available? Does the patient receive molecular profiling where appropriate? Can pathology, imaging and biomarkers establish what is actually driving the disease?
Then comes the next question: what can we do about it?
Is there an appropriate treatment? Is there a clinical trial? Can evidence generated across hundreds or thousands of patients be translated into the right decision for this person? And does the health system have the infrastructure, workforce and reimbursement pathways to act?
This is where IAPM has an important role.
The challenge is now to build the bridge between scientific possibility, healthcare delivery and political decision-making.
IAPM brings patients, clinicians, researchers, diagnostics, industry and health-system experts into the same conversation with policymakers, translating evidence into practical choices on screening, diagnostics, reimbursement, clinical trials and system readiness.
Because innovation does not reach patients by itself.
A biomarker may exist, but somebody must decide whether it is funded. A diagnostic may demonstrate clinical value, but somebody must determine where it belongs in the pathway.
A therapy may be approved, but access still depends on national policy and implementation.
The Dublin conference will therefore follow the patient journey from early detection and diagnosis, through advanced diagnostics and biomarkers, into clinical trials, treatment access and health-system readiness.
Personalised medicine is not personalised simply because we can sequence a tumour or identify a biomarker.
It becomes personalised when policy and healthcare systems can turn that knowledge into the right decision for the person sitting in front of the clinician.
Science increasingly allows us to understand disease at the level of the individual. Policy must now be able to respond at the same level.
Behind every cohort of 300 patients are 300 individual lives.
Learn more about IAPM: IPM Brief – Issue 33 | Who Regulates the Future?”
Other articles about IAPM on OncoDaily.